Iradimed Co (IRMD)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $1.09B
Last updated: Nov 17, 2026 at 4:38 PM ET
Iradimed Co (IRMD) Statistics
Iradimed (IRMD) has a market cap of $1.09B and an enterprise value of $1.03B. Its trailing P/E is 42.8x.
Total Valuation
Enterprise value is 5.80% below the market cap, as cash exceeds debt.
| Market Cap | $1.09B |
|---|---|
| Enterprise Value | $1.03B |
| Latest price (Nov 17, 2026) | $83.45 |
Key Dates
The next earnings report is expected on Feb 8, 2027, covering the quarter ending Dec 31, 2026. The last ex-dividend date was Nov 13, 2026.
| Next Earnings Date | Feb 8, 2027 (expected) |
|---|---|
| Last Earnings Date | Oct 30, 2026 |
| Last Ex-Dividend Date | Nov 13, 2026 |
| Next Payment Date | Nov 27, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 11.9x and 10.0x. Its year-end P/E ranged from 15.9x to 72.1x from 2016 to 2025.
| P/E Ratio | 42.8x |
|---|---|
| Forward P/E | 39.0x |
| P/S Ratio | 11.9x |
| Forward P/S | 11.8x |
| P/B Ratio | 10.0x |
| P/TBV Ratio | 10.4x |
| P/FCF Ratio | 41.0x |
| P/OCF Ratio | 40.2x |
| PEG Ratio | 3.8 |
Enterprise Valuation
Counting debt and cash, the company is valued at 30.6x EBITDA and 38.6x free cash flow.
| EV / Earnings | 42.9x |
|---|---|
| EV / Sales | 11.5x |
| EV / EBITDA | 30.6x |
| EV / EBIT | 33.0x |
| EV / FCF | 38.6x |
Price Statistics
The stock is down 0.11% over 52 weeks and trades 1.96% below its 50-day average.
| Beta (1Y) | 0.73 |
|---|---|
| 52-Week Change | -0.11% |
| 1-Month Change | -4.57% |
| 3-Month Change | -4.30% |
| 6-Month Change | -4.26% |
| 5-Year Change | +105.47% |
| 10-Year Change | +711.43% |
| Total Return (1Y) | +1.44% |
| Total Return (3Y CAGR) | +27.33% |
| Total Return (5Y CAGR) | +19.06% |
| Return vs SPY (1Y) | -13.79% |
| Max Drawdown (1Y) | -27.05% |
| Max Drawdown (3Y) | -27.05% |
| Sharpe Ratio (1Y) | -0.07 |
| Correlation with SPY (1Y) | 0.32 |
| 50-Day Average | $85.12 |
| 200-Day Average | $91.30 |
| 52-Week Range | $76.17 to $106.95 |
| RSI (14 Days) | 45.3 |
| Average Volume (20 Days) | 131.05K |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 8.99x current liabilities, and total debt is 0.00x shareholder equity.
| Current Ratio | 8.99x |
|---|---|
| Quick Ratio | 7.68x |
| Debt / Equity | 0.00x |
Returns and Efficiency
Return on equity is 22.53% over the last 12 months, against a 5-year average of 20.06%.
| Return on Equity (ROE) | 22.53% |
|---|---|
| Return on Assets (ROA) | 19.81% |
| Return on Capital Employed (ROCE) | 28.10% |
| ROE (5Y Average) | 20.06% |
| ROA (5Y Average) | 17.03% |
| ROIC (5Y Average) | 22.96% |
| Asset Turnover | 0.76x |
| Inventory Turnover | 1.70x |
| Receivables Turnover | 6.65x |
| Cash Conversion Cycle | 234 days |
Taxes
Income tax took 22.92% of pretax income over the last 12 months.
| Income Tax (TTM) | $7.13M |
|---|---|
| Effective Tax Rate | 22.92% |
Scores
IRMD has an Altman Z-Score of 47.06, in the safe zone above 2.99, and a Piotroski F-Score of 5 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 47.06 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 5 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $89.34M over the last 12 months is up 10.97% from the 12 months before.
| Revenue | $89.34M |
|---|---|
| Revenue Growth (YoY) | +10.97% |
| Gross Profit | $67.46M |
| Operating Income | $28.86M |
| Pretax Income | $31.12M |
| Net Income | $23.98M |
| EBITDA | $32.77M |
| EBIT | $31.12M |
| Reported EPS (TTM) | $1.95 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 87.92% of the $121.07M in total assets.
| Cash and Equivalents | $63.29M |
|---|---|
| Total Debt | $0 |
| Net Cash | $63.29M |
| Net Cash Per Share | $4.95 |
| Working Capital | $82.48M |
| Shareholder Equity | $106.45M |
| Book Value Per Share | $8.33 |
| Tangible Book Value | $103.04M |
| Tangible Book Per Share | $8.06 |
| Total Assets | $121.07M |
| Total Liabilities | $14.62M |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $1.13M of capital spending, operating cash flow left $26.02M of free cash flow.
| Operating Cash Flow | $27.15M |
|---|---|
| Capital Expenditures | $1.13M |
| Free Cash Flow | $26.02M |
| FCF Per Share | $2.03 |
| Depreciation and Amortization | $1.66M |
| Dividends Paid | $16.23M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is 32.30%, against a 5-year average of 28.91%.
| Gross Margin | 75.51% |
|---|---|
| Operating Margin | 32.30% |
| Pretax Margin | 34.83% |
| Net Margin | 26.85% |
| EBITDA Margin | 36.68% |
| EBIT Margin | 34.83% |
| FCF Margin | 29.12% |
| Gross Margin (5Y Average) | 76.86% |
| Operating Margin (5Y Average) | 28.91% |
| Net Margin (5Y Average) | 25.13% |
Growth
Revenue grew 16.28% a year over 3 years, and EPS 20.77% a year.
| Revenue Growth (3Y CAGR) | +16.28% |
|---|---|
| Revenue Growth (5Y CAGR) | +21.45% |
| EPS Growth (3Y CAGR) | +20.77% |
| EPS Growth (5Y CAGR) | +36.18% |
| FCF Growth (3Y CAGR) | +26.48% |
| FCF Growth (5Y CAGR) | +26.11% |
| Operating Income Growth (3Y CAGR) | +18.72% |
| Book Value Per Share Growth (2Y CAGR) | +14.49% |
| Tangible Book Per Share Growth (2Y CAGR) | +14.46% |
Dividends and Yields
IRMD pays out 42.65% of earnings as dividends.
| Dividend Per Share (Annual) | $0.80 |
|---|---|
| Dividend Yield | 0.96% |
| Payment Schedule | Quarterly |
| Payout Ratio | 42.65% |
| FCF Payout Ratio | 62.37% |
| Earnings Yield | 2.34% |
| FCF Yield | 2.44% |
| Shareholder Yield | 1.52% |
Peer Position
Against 9 similar companies, IRMD has the 2nd highest P/E.
P/E RatioPeer median 11.5x
P/S RatioPeer median 1.5x
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +4.29%
| P/E Ratio | 42.8x vs 11.5x median |
|---|---|
| P/S Ratio | 11.9x vs 1.5x median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +10.97% vs +4.29% median |
Analyst Forecast
Consensus estimates put revenue growth at 10.50% and EPS growth at 12.65% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +10.50% |
|---|---|
| EPS Growth Forecast (2Y CAGR) | +12.65% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About IRMD
What is IRMD's market cap?
Iradimed has a market cap of $1.09B. Its enterprise value, which adds debt and subtracts cash, is $1.03B.
What is IRMD's P/E ratio?
Iradimed has a trailing P/E ratio of 42.8x and a forward P/E of 39.0x.
How many shares of IRMD are outstanding?
Iradimed has 12.79M shares outstanding. The count is up 0.52% from a year earlier.
Does IRMD pay a dividend?
Yes. Iradimed pays $0.80 a share a year, a dividend yield of 0.96%.
How much debt does IRMD have?
Iradimed has $0 of total debt and $63.29M of cash and equivalents, a net cash position of $63.29M.
IRMD pages: Overview, Dividends, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors, Government Contracts